Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
POLK-38
- Development stage
- Preclinical
- Lead developer
- Polku Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
POLK-38 is an orally active, brain-penetrant small molecule modulator of prolyl oligopeptidase (PREP) developed by Polku Therapeutics, a spinout from the University of Helsinki. It targets the PREP–PP2A (protein phosphatase 2A) pathway to restore protein homeostasis and promote tau dephosphorylation. In preclinical models of tauopathy, such as the PS19 mouse model, oral administration of POLK-38 has demonstrated significant efficacy in reducing brain tau pathology and improving spatial learning. It is being developed as a disease-modifying therapy for neurodegenerative disorders, including Alzheimer's disease, frontotemporal dementia, and traumatic brain injury.
02
Targets
MAPT (Microtubule-associated protein tau)PREP (Prolyl Oligopeptidase)PP2A (Protein phosphatase 2A)
Beyond the preview
Go deeper on POLK-38.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on POLK-38.